This clinical trial is studying a medication called tozorakimab in people who have Chronic Obstructive Pulmonary Disease, also known as COPD. COPD is a long-term lung condition that makes it difficult to breathe and can cause episodes called exacerbations, which are sudden worsening of symptoms. This study is specifically for people with COPD who have had these worsening episodes in the past. Tozorakimab is given as an injection under the skin and will be used together with the usual medications that people are already taking for their COPD.
The purpose of this study is to look at the long-term safety and how well people tolerate tozorakimab when it is added to their standard care. This is an extension study, which means it is designed for people who have already participated in earlier studies of this medication. The study will continue to give tozorakimab to participants to see if it remains safe over a longer period of time. The medication will be given regularly over a period that can last up to 36 months.
During the study, participants will receive tozorakimab and will be monitored for any side effects or health changes. The study team will collect information about any adverse events that occur, perform laboratory tests, and track how participants are doing overall. This information will help researchers understand whether tozorakimab is safe for long-term use in people with COPD who have experienced exacerbations.
France 
